NCT00311896

Phase 3Interventional

Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.

View on ClinicalTrials.gov ↗

Timeline

Start date: Jul 1, 2005
Primary completion: Feb 1, 2009
Completion date: Dec 1, 2010
First posted: —
Last posted: —
Enrollment: 402
Arms / groups: 2 / —
Source: AACT · pre-existing

Sponsors

Clinica Universidad de NavarraLead sponsor
Hospital Universitario Central de AsturiasOverall official - principal investigator
University of BarcelonaOverall official - principal investigator
Universidad Autonoma de MadridOverall official - principal investigator
Hospital Morales MeseguerOverall official - principal investigator
Arad District HospitalOverall official - principal investigator
Filantropia District HospitalOverall official - principal investigator
Oncology Medical Center IasiOverall official - principal investigator
Oncology Institute Cuj-NapocaOverall official - principal investigator
University of ZaragozaOverall official - principal investigator
Hospital Universitario Puerta del MarOverall official - principal investigator
University AlicanteOverall official - principal investigator
University of ValenciaOverall official - principal investigator
OsakidetzaOverall official - principal investigator
Spitalul Sfanta Maria, BucharestOverall official - principal investigator
Clinica Universidad de NavarraOverall official - principal investigator
Clinica Universidad de NavarraStudy chair
Badalona Hospital Germans Trias i PujolOverall official - principal investigator

Drugs studied

enoxaparin

Indications studied

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.